BioRestorative Therapies, Inc. (BRTX)

1.3650 -0.0850 (-5.88%) As of 03:57PM EDT. Market open.

BioRestorative Therapies, Inc.

40 Marcus Drive
Suite 1
Melville, NY 11747
United States
631 760 8100
https://www.biorestorative.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 11

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Lance Alstodt	Chairman of the Board, President & CEO	954.17k	N/A	1971
Mr. Robert Eugene Kristal	Chief Financial Officer	368.12k	N/A	1968
Mr. Francisco J. Silva	Chief Scientist, VP of Research & Development, Secretary and Director	891.67k	N/A	1975
Mr. Robert Paccasassi	Vice President of Quality Assurance & Regulatory Compliance	233.95k	N/A	1969
Dr. Wayne J. Olan M.D.	Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Corporate governance

BioRestorative Therapies, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.